ARC Therapies Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Seed

  • Investors
  • 2

ARC Therapies General Information

Description

Developer of cell medicine and cancer immunotherapy intended for cancer treatment. The company develops regenerative medicine and chimeric antigen receptor-T cells that attack tumors, demonstrating efficacy in overcoming the adverse environment near tumors, enabling users to improve their quality of life and to continue their social life without change.

Contact Information

Website
www.arctherapies.inc
Formerly Known As
Sustainable Cell Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 8, Sugacho Shinjuku-ku
  • Tokyo, 160-0018
  • Japan
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 8, Sugacho Shinjuku-ku
  • Tokyo, 160-0018
  • Japan

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ARC Therapies Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Seed Round 01-May-2022 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view ARC Therapies’s complete valuation and funding history, request access »

ARC Therapies Patents

  • 9

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • 4

    Pending

  • Expiring in next 12 mo

ARC Therapies Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-7818147-B1 Effector t cells and pharmaceutical compositions containing same Active 23-Jan-2025
JP-2026126088-A Effector t cells and pharmaceutical compositions containing them Active 23-Jan-2025
WO-2026160421-A1 Effector t-cell and pharmaceutical composition containing same Pending 23-Jan-2025
AU-2025207075-A1 Survivor t cells, survivor t cell population, and pharmaceutical composition Pending 09-Jan-2024
JP-2025110414-A Survivor t cells, survivor t cell population, and pharmaceutical composition Pending 09-Jan-2024 C07K14/435
To view ARC Therapies’s complete patent history, request access »

ARC Therapies Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Healthcare Innovation Venture Capital Minority
LINK-J Accelerator/Incubator Minority
To view ARC Therapies’s complete investors history, request access »

Ready to get started?

Request a free trial

ARC Therapies FAQs

  • When was ARC Therapies founded?

    ARC Therapies was founded in 2020.

  • Where is ARC Therapies headquartered?

    ARC Therapies is headquartered in Tokyo, Japan.

  • What industry is ARC Therapies in?

    ARC Therapies’s primary industry is Biotechnology.

  • Is ARC Therapies a private or public company?

    ARC Therapies is a Private company.

  • What is ARC Therapies’s current revenue?

    The current revenue for ARC Therapies is .

  • Who are ARC Therapies’s investors?

    Healthcare Innovation and LINK-J have invested in ARC Therapies.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process